bluuebunny/crossref_metadata_2025 huggingface dataset:
Figure S2 from The ATR Inhibitor AZD6738 Synergizes with Gemcitabine In Vitro and In Vivo to Induce Pancreatic Ductal Adenocarcinoma Regression
Authors: Wallez Yann , Dunlop Charles R. , Johnson Timothy Isaac , Koh Siang-Boon , Fornari Chiara , Yates James W.T. , Bernaldo de Quirós Fernández Sandra , Lau Alan , Richards Frances M. , Jodrell Duncan I.
Published: April 2023

AZD6738 and gemcitabine synergistically inhibit cell growth in a panel of PDAC cell lines
Figure S4 from Specific RITA Modification Produces Hyperselective Cytotoxicity While Maintaining In Vivo Antitumor Efficacy
Authors: Peyser Brian D. , Hermone Ann , Salamoun Joseph M. , Burnett James C. , Hollingshead Melinda G. , McGrath Connor F. , Gussio Rick , Wipf Peter
Published: April 2023

Complete A-498 subcutaneous xenograft responses for all doses and schedules.
Figure S1 from The ATR Inhibitor AZD6738 Synergizes with Gemcitabine In Vitro and In Vivo to Induce Pancreatic Ductal Adenocarcinoma Regression
Authors: Wallez Yann , Dunlop Charles R. , Johnson Timothy Isaac , Koh Siang-Boon , Fornari Chiara , Yates James W.T. , Bernaldo de Quirós Fernández Sandra , Lau Alan , Richards Frances M. , Jodrell Duncan I.
Published: April 2023

AZD6738 abrogates the gemcitabine-induced checkpoint activation
Figure S3 from Specific RITA Modification Produces Hyperselective Cytotoxicity While Maintaining In Vivo Antitumor Efficacy
Authors: Peyser Brian D. , Hermone Ann , Salamoun Joseph M. , Burnett James C. , Hollingshead Melinda G. , McGrath Connor F. , Gussio Rick , Wipf Peter
Published: April 2023

Correlation of reported RITA analogs with SULT1A1 mRNA expression.
Figure S2 from Specific RITA Modification Produces Hyperselective Cytotoxicity While Maintaining In Vivo Antitumor Efficacy
Authors: Peyser Brian D. , Hermone Ann , Salamoun Joseph M. , Burnett James C. , Hollingshead Melinda G. , McGrath Connor F. , Gussio Rick , Wipf Peter
Published: April 2023

Mean graph representation of full NCI-60 Log(GI50) results.
Supplementary Methods and Figures S1-S4 from Mechanisms Behind Resistance to PI3K Inhibitor Treatment Induced by the PIM Kinase
Authors: Song Jin H. , Singh Neha , Luevano Libia A. , Padi Sathish K.R. , Okumura Koichi , Olive Virginie , Black Stephen M. , Warfel Noel A. , Goodrich David W. , Kraft Andrew S.
Published: April 2023

Supplementary Methods Supplementary References Figure S1. PIM and PI3K/AKT inhibitors synergize to suppress PCa cell growth and survival. Figure S2. PIM1 induces expression of ROS scavengers by NRF2 transcription activity. Figure S3. PIM1 promotes glucose carbon flux in various metabolic pathways. Figure S4. PIM and PI3K/AKT inhibitors downregulate NRF2 antioxidant response leading to oxidative DNA damages.
Supplementary Data from Suppression of Prostate Cancer Pathogenesis Using an MDA-9/Syntenin (SDCBP) PDZ1 Small-Molecule Inhibitor
Authors: Das Swadesh K. , Kegelman Timothy P. , Pradhan Anjan K. , Shen Xue-Ning , Bhoopathi Praveen , Talukdar Sarmistha , Maji Santanu , Sarkar Devanand , Emdad Luni , Fisher Paul B.
Published: April 2023

Supplementary Information and figure legends.
Supplementary Video 7 from Multiplex Three-Dimensional Mapping of Macromolecular Drug Distribution in the Tumor Microenvironment
Authors: Lee Steve Seung-Young , Bindokas Vytautas P. , Kron Stephen J.
Published: April 2023

3D rendering of doxorubicin delivery to tumor in mouse treated with PEGylated liposomal doxorubicin (Doxil), showing cell uptake at 4 h after injection. Doxorubicin bound to nuclear DNA (yellow) and i.v. CD31 (cyan).
Supplementary Video 6 from Multiplex Three-Dimensional Mapping of Macromolecular Drug Distribution in the Tumor Microenvironment
Authors: Lee Steve Seung-Young , Bindokas Vytautas P. , Kron Stephen J.
Published: April 2023

3D rendering of anti-EGFR and IgG isotype antibody distribution in the lung cancer PDX tumor nest at 1 h after injection. i.v. EGFR (green), i.v. IgG (red), and i.v. CD31 (cyan).
Supplementary Video 5 from Multiplex Three-Dimensional Mapping of Macromolecular Drug Distribution in the Tumor Microenvironment
Authors: Lee Steve Seung-Young , Bindokas Vytautas P. , Kron Stephen J.
Published: April 2023

3D rendering of anti-Her2 and IgG isotype antibody distribution in the BALB-NeuT tumor nest at 1 h after injection. i.v. Her2 (green), i.v. IgG (red), and i.v. CD31 (cyan).
Supplementary Figure 1 from The STAT3 Inhibitor Galiellalactone Reduces IL6-Mediated AR Activity in Benign and Malignant Prostate Models
Authors: Handle Florian , Puhr Martin , Schaefer Georg , Lorito Nicla , Hoefer Julia , Gruber Martina , Guggenberger Fabian , Santer Frédéric R. , Marques Rute B. , van Weerden Wytske M. , Claessens Frank , Erb Holger H.H. , Culig Zoran
Published: April 2023

Canonical activation of the AR (by R1881) and of STAT3 (by IL6) are rapid processes
Supplementary Video 4 from Multiplex Three-Dimensional Mapping of Macromolecular Drug Distribution in the Tumor Microenvironment
Authors: Lee Steve Seung-Young , Bindokas Vytautas P. , Kron Stephen J.
Published: April 2023

3D rendering of different types of microvessels and their permeability with regards to anti-PD-L1 antibody drug penetration into tumor. SMA (green), CD31 (cyan), ER-TR7 (magenta), and i.v. PD-L1 (red).
Supplementary Video 3 from Multiplex Three-Dimensional Mapping of Macromolecular Drug Distribution in the Tumor Microenvironment
Authors: Lee Steve Seung-Young , Bindokas Vytautas P. , Kron Stephen J.
Published: April 2023

3D rendering of anti-PD-L1 antibody distribution in the tumor microenvironment at 10 min after injection. Her2 (green), CD8 (yellow), i.v. PD-L1 (red), CD31 (cyan), and PD-L1 (magenta).
Figures S1-S8 from Targeting Phosphatidylserine with Calcium-Dependent Protein–Drug Conjugates for the Treatment of Cancer
Authors: Li Ran , Chiguru Srinivas , Li Li , Kim Dongyoung , Velmurugan Ramraj , Kim David , Devanaboyina Siva Charan , Tian Hong , Schroit Alan , Mason Ralph P. , Ober Raimund J. , Ward E. Sally
Published: April 2023

Document containing supplementary figures; Figure S1. Gel filtration analyses of recombinant Fc fusions; Figure S2. Exposure of PS by tumor endothelial cells; Figure S3. Subcellular trafficking analyses of bivalent and tetravalent Fc-Syt1 fusions; Figure S4. Mass spectrometry analyses of MMAE-conjugated Fc fusions; Figure S5. Subcellular trafficking analyses of MMAE-conjugated Fc fusions; Figure S6. Internalization behavior of MMAE-conjugated Fc fusions in cells that expose PS; Figure S7. Body weights of mice during treatment with MMAE-conjugated Fc fusions; Figure S8. Mass spectrometry analyses of MMAE-conjugated Fc-Syt1(DN).
Supplementary Video 2 from Multiplex Three-Dimensional Mapping of Macromolecular Drug Distribution in the Tumor Microenvironment
Authors: Lee Steve Seung-Young , Bindokas Vytautas P. , Kron Stephen J.
Published: April 2023

High resolution 3D rendering of vascular penetration of anti-PD-L1 antibody drug in TUBO tumor. i.v. PD-L1 (red) and i.v. CD31 (cyan).
Supplementary data Figure S4 from Anti-HER2 scFv-Directed Extracellular Vesicle-Mediated mRNA-Based Gene Delivery Inhibits Growth of HER2-Positive Human Breast Tumor Xenografts by Prodrug Activation
Authors: Wang Jing-Hung , Forterre Alexis V. , Zhao Jinjing , Frimannsson Daniel O. , Delcayre Alain , Antes Travis J. , Efron Bradley , Jeffrey Stefanie S. , Pegram Mark D. , Matin A.C.
Published: April 2023

siRNA loading into EVs
Supplementary Video 1 from Anti-HER2 scFv-Directed Extracellular Vesicle-Mediated mRNA-Based Gene Delivery Inhibits Growth of HER2-Positive Human Breast Tumor Xenografts by Prodrug Activation
Authors: Wang Jing-Hung , Forterre Alexis V. , Zhao Jinjing , Frimannsson Daniel O. , Delcayre Alain , Antes Travis J. , Efron Bradley , Jeffrey Stefanie S. , Pegram Mark D. , Matin A.C.
Published: April 2023

EVHB three-dimensional structure
Supplementary Tables S1-S2 from Dual Targeting of Epithelial Ovarian Cancer Via Folate Receptor α and the Proton-Coupled Folate Transporter with 6-Substituted Pyrrolo[2,3-d]pyrimidine Antifolates
Authors: Hou Zhanjun , Gattoc Leda , O'Connor Carrie , Yang Si , Wallace-Povirk Adrianne , George Christina , Orr Steve , Polin Lisa , White Kathryn , Kushner Juiwanna , Morris Robert T. , Gangjee Aleem , Matherly Larry H.
Published: April 2023

Table S1: Epithelial ovarian cancer (EOC) tissue cDNA array for real-time RT-PCR (Figures 2A and 2B). Table S2. Epithelial ovarian cancer (EOC) tissue microarray (TMA) for immunohistochemistry (IHC; Figures 2C and 2D).
Figure S3 from Anti-HER2 scFv-Directed Extracellular Vesicle-Mediated mRNA-Based Gene Delivery Inhibits Growth of HER2-Positive Human Breast Tumor Xenografts by Prodrug Activation
Authors: Wang Jing-Hung , Forterre Alexis V. , Zhao Jinjing , Frimannsson Daniel O. , Delcayre Alain , Antes Travis J. , Efron Bradley , Jeffrey Stefanie S. , Pegram Mark D. , Matin A.C.
Published: April 2023

EV markers Western blot
Supplementary Data from Selective Killing of SMARCA2- and SMARCA4-deficient Small Cell Carcinoma of the Ovary, Hypercalcemic Type Cells by Inhibition of EZH2: In Vitro and In Vivo Preclinical Models
Authors: Chan-Penebre Elayne , Armstrong Kelli , Drew Allison , Grassian Alexandra R. , Feldman Igor , Knutson Sarah K. , Kuplast-Barr Kristy , Roche Maria , Campbell John , Ho Peter , Copeland Robert A. , Chesworth Richard , Smith Jesse J. , Keilhack Heike , Ribich Scott A.
Published: April 2023

PDF File -1 MB, Supplemental data is to further support the statements made it the main text. Captions: Supplemental Table 1: Cell Lines used in the CRISPR pooled screen. Supplemental Table 2: Table of ovarian lines screened for tazemetostat sensitivity along with mutational and protein status for SMARCA2, SMARCA4, and ARID1A. Supplemental Table 3: p-values of COV434 SCCOHT cell line treated with tazemetostat. Supplemental Table 4: p-values of JHOC-5 clear cell ovarian cell line treated with tazemetostat. Supplemental Table 5: p-values of cell cycle analysis after tazemetostat treatment. Supplemental Table 6: p-values of apoptosis analysis after tazemetostat treatment. Supplemental Table 7: LogP scores for SWI/SNF components in ovarian lines +/- tazemetostat treatment. Supplemental Figure 1: Baseline measurement of histone 3 lysine 27 trimethyl mark and EZH2. Supplemental Figure 2a: Growth curves of SCCOHT and ovarian cancer cell lines treated with tazemetostat. Supplemental Figure 2b: Growth curves of SCCOHT and ovarian cancer cell lines treated with EPZ-007210. Supplemental Figure 3: Reduction in H3K27me3 mark after treatment. Supplemental Figure 4a: Sensitivity to PLK1 knockout as pan-essential in CRISPR pooled screen. Supplemental Figure 4b: Control sgRNAs from CRISPR pooled screen. Supplemental Figure 5: TOV112D xenograft tumor growth inhibition, tumor volume, and methyl mark. Supplemental Figure 6: body weights of mice treated with tazemetostat. Supplemental Figure 7: measured blood plasma levels of tazemetostat from xenograft mice.
Figure S2 from Anti-HER2 scFv-Directed Extracellular Vesicle-Mediated mRNA-Based Gene Delivery Inhibits Growth of HER2-Positive Human Breast Tumor Xenografts by Prodrug Activation
Authors: Wang Jing-Hung , Forterre Alexis V. , Zhao Jinjing , Frimannsson Daniel O. , Delcayre Alain , Antes Travis J. , Efron Bradley , Jeffrey Stefanie S. , Pegram Mark D. , Matin A.C.
Published: April 2023

TEM images of EVs
Figure S1 from Anti-HER2 scFv-Directed Extracellular Vesicle-Mediated mRNA-Based Gene Delivery Inhibits Growth of HER2-Positive Human Breast Tumor Xenografts by Prodrug Activation
Authors: Wang Jing-Hung , Forterre Alexis V. , Zhao Jinjing , Frimannsson Daniel O. , Delcayre Alain , Antes Travis J. , Efron Bradley , Jeffrey Stefanie S. , Pegram Mark D. , Matin A.C.
Published: April 2023

EVHB protein sequence
Table S2 from Prospective Clinical Sequencing of Adult Glioma
Authors: Zheng Siyuan , Alfaro-Munoz Kristin , Wei Wei , Wang Xiaojing , Wang Fang , Eterovic Agda Karina , Shaw Kenna R. Mills , Meric-Bernstam Funda , Fuller Gregory N. , Chen Ken , Verhaak Roel G. , Mills Gordon B. , Yung W.K. Alfred , Weathers Shiao-Pei , de Groot John F.
Published: April 2023

Univariate and multivariate survival analysis.
Table S3 from Metabolite Profiling Reveals the Glutathione Biosynthetic Pathway as a Therapeutic Target in Triple-Negative Breast Cancer
Authors: Beatty Alexander , Fink Lauren S. , Singh Tanu , Strigun Alexander , Peter Erik , Ferrer Christina M. , Nicolas Emmanuelle , Cai Kathy Q. , Moran Timothy P. , Reginato Mauricio J. , Rennefahrt Ulrike , Peterson Jeffrey R.
Published: April 2023

Table S3. Comparison of the levels of 155 intracellular metabolites across the three metabolic subtypes, related to Figure 1, included as a separate Excel file. The table is ordered according to ontology classes 1 and 2 of the measured metabolite. Explanations for the values presented in each of the columns can be found under the "Legend" tab in the spreadsheet.
Table S1 from Prospective Clinical Sequencing of Adult Glioma
Authors: Zheng Siyuan , Alfaro-Munoz Kristin , Wei Wei , Wang Xiaojing , Wang Fang , Eterovic Agda Karina , Shaw Kenna R. Mills , Meric-Bernstam Funda , Fuller Gregory N. , Chen Ken , Verhaak Roel G. , Mills Gordon B. , Yung W.K. Alfred , Weathers Shiao-Pei , de Groot John F.
Published: April 2023

Genes sequenced by the T200 and T200.1 platforms.
Figures S1-S4 from Prospective Clinical Sequencing of Adult Glioma
Authors: Zheng Siyuan , Alfaro-Munoz Kristin , Wei Wei , Wang Xiaojing , Wang Fang , Eterovic Agda Karina , Shaw Kenna R. Mills , Meric-Bernstam Funda , Fuller Gregory N. , Chen Ken , Verhaak Roel G. , Mills Gordon B. , Yung W.K. Alfred , Weathers Shiao-Pei , de Groot John F.
Published: April 2023

S1 shows intratumor mutation heterogeneity between two specimens of one tumor. S2 describes mutational load of the patient cohort. S3 shows survival difference based on histology. S4 shows mutational signature.
Supplementary Figures from Metabolite Profiling Reveals the Glutathione Biosynthetic Pathway as a Therapeutic Target in Triple-Negative Breast Cancer
Authors: Beatty Alexander , Fink Lauren S. , Singh Tanu , Strigun Alexander , Peter Erik , Ferrer Christina M. , Nicolas Emmanuelle , Cai Kathy Q. , Moran Timothy P. , Reginato Mauricio J. , Rennefahrt Ulrike , Peterson Jeffrey R.
Published: April 2023

Figures S1-S5
Supplementary Figures 1-4 from Concurrent HER or PI3K Inhibition Potentiates the Antitumor Effect of the ERK Inhibitor Ulixertinib in Preclinical Pancreatic Cancer Models
Authors: Jiang Hongmei , Xu Mai , Li Lin , Grierson Patrick , Dodhiawala Paarth , Highkin Maureen , Zhang Daoxiang , Li Qiong , Wang-Gillam Andrea , Lim Kian-Huat
Published: April 2023

Supplementary Figure 1. Ulixertinib potentiates gemcitabine effect and this combination is well tolerated in mice; Supplementary Figure 2. Pharmacologic ERK inhibition increases p-MEK, ERK and AKT; Supplementary Figure 3. Ulixertinib synergizes with HER inhibitors; Supplementary Figure 4. Ulixertinib synergizes with PI3K Inhibitor
supplementary figure and table legend from Identification of Pharmacodynamic Transcript Biomarkers in Response to FGFR Inhibition by AZD4547
Authors: Delpuech Oona , Rooney Claire , Mooney Lorraine , Baker Dawn , Shaw Robert , Dymond Michael , Wang Dennis , Zhang Pei , Cross Sarah , Veldman-Jones Margaret , Wilson Joanne , Davies Barry R. , Dry Jonathan R. , Kilgour Elaine , Smith Paul D.
Published: April 2023

supplementary figures and tables legend
supplementary Table 6 from Identification of Pharmacodynamic Transcript Biomarkers in Response to FGFR Inhibition by AZD4547
Authors: Delpuech Oona , Rooney Claire , Mooney Lorraine , Baker Dawn , Shaw Robert , Dymond Michael , Wang Dennis , Zhang Pei , Cross Sarah , Veldman-Jones Margaret , Wilson Joanne , Davies Barry R. , Dry Jonathan R. , Kilgour Elaine , Smith Paul D.
Published: April 2023

Differential gene expression and two statistical analysis of ANC3A xenograft after treatment by AZD4547 and/or AZD5363 compared to vehicle group, and Combination group compared to singled agent.
supplementary Table 5 from Identification of Pharmacodynamic Transcript Biomarkers in Response to FGFR Inhibition by AZD4547
Authors: Delpuech Oona , Rooney Claire , Mooney Lorraine , Baker Dawn , Shaw Robert , Dymond Michael , Wang Dennis , Zhang Pei , Cross Sarah , Veldman-Jones Margaret , Wilson Joanne , Davies Barry R. , Dry Jonathan R. , Kilgour Elaine , Smith Paul D.
Published: April 2023

Statistical analysis of gene modulation between FGFR1, 2 and 3 dysregulated cell lines.
supplementary Table 3 from Identification of Pharmacodynamic Transcript Biomarkers in Response to FGFR Inhibition by AZD4547
Authors: Delpuech Oona , Rooney Claire , Mooney Lorraine , Baker Dawn , Shaw Robert , Dymond Michael , Wang Dennis , Zhang Pei , Cross Sarah , Veldman-Jones Margaret , Wilson Joanne , Davies Barry R. , Dry Jonathan R. , Kilgour Elaine , Smith Paul D.
Published: April 2023

Gene symbol and primer ID used for targeted profiling on Fluidigm arrays
supplementary Table 2 from Identification of Pharmacodynamic Transcript Biomarkers in Response to FGFR Inhibition by AZD4547
Authors: Delpuech Oona , Rooney Claire , Mooney Lorraine , Baker Dawn , Shaw Robert , Dymond Michael , Wang Dennis , Zhang Pei , Cross Sarah , Veldman-Jones Margaret , Wilson Joanne , Davies Barry R. , Dry Jonathan R. , Kilgour Elaine , Smith Paul D.
Published: April 2023

55 FGFR2 modified dynamic biomarker after treatment by AZD4547
Supplementary Table S5 from TGFβ-induced SMAD4-dependent Apoptosis Proceeded by EMT in CRC
Authors: Siraj Abdul K. , Pratheeshkumar Poyil , Divya Sasidharan Padmaja , Parvathareddy Sandeep Kumar , Bu Rong , Masoodi Tariq , Kong Yan , Thangavel Saravanan , Al-Sanea Nasser , Ashari Luai H. , Abduljabbar Alaa , Al-Homoud Samar , Al-Dayel Fouad , Al-Kuraya Khawla S.
Published: April 2023

Correlation of Smad4 alteration with clinico-pathological parameters in colorectal carcinoma
Supplementary Table 3 from An EGFR-Induced Drosophila Lung Tumor Model Identifies Alternative Combination Treatments
Authors: Bossen Judith , Uliczka Karin , Steen Line , Pfefferkorn Roxana , Mai Mandy Mong-Quyen , Burkhardt Lia , Spohn Michael , Bruchhaus Iris , Fink Christine , Heine Holger , Roeder Thomas
Published: April 2023

Whole animal screening of Drosophila larvae with FDA approved compound
Supplementary Table S2 from TGFβ-induced SMAD4-dependent Apoptosis Proceeded by EMT in CRC
Authors: Siraj Abdul K. , Pratheeshkumar Poyil , Divya Sasidharan Padmaja , Parvathareddy Sandeep Kumar , Bu Rong , Masoodi Tariq , Kong Yan , Thangavel Saravanan , Al-Sanea Nasser , Ashari Luai H. , Abduljabbar Alaa , Al-Homoud Samar , Al-Dayel Fouad , Al-Kuraya Khawla S.
Published: April 2023

List of validated smad4 somatic mutation
Supplementary Table 2 from An EGFR-Induced Drosophila Lung Tumor Model Identifies Alternative Combination Treatments
Authors: Bossen Judith , Uliczka Karin , Steen Line , Pfefferkorn Roxana , Mai Mandy Mong-Quyen , Burkhardt Lia , Spohn Michael , Bruchhaus Iris , Fink Christine , Heine Holger , Roeder Thomas
Published: April 2023

KEGG pathway analysis of differentially transcribed genes between EGFR OE and control airways
Supplementary Table S1 from TGFβ-induced SMAD4-dependent Apoptosis Proceeded by EMT in CRC
Authors: Siraj Abdul K. , Pratheeshkumar Poyil , Divya Sasidharan Padmaja , Parvathareddy Sandeep Kumar , Bu Rong , Masoodi Tariq , Kong Yan , Thangavel Saravanan , Al-Sanea Nasser , Ashari Luai H. , Abduljabbar Alaa , Al-Homoud Samar , Al-Dayel Fouad , Al-Kuraya Khawla S.
Published: April 2023

Clinicopathological variables for the patient cohort (n=1050)
Supplementary Table 1 from An EGFR-Induced Drosophila Lung Tumor Model Identifies Alternative Combination Treatments
Authors: Bossen Judith , Uliczka Karin , Steen Line , Pfefferkorn Roxana , Mai Mandy Mong-Quyen , Burkhardt Lia , Spohn Michael , Bruchhaus Iris , Fink Christine , Heine Holger , Roeder Thomas
Published: April 2023

Differentially regulated genes in response to ectopic EGFR overexpression in the airway epithelium of Drosophila
Supplementary Figure S2 from TGFβ-induced SMAD4-dependent Apoptosis Proceeded by EMT in CRC
Authors: Siraj Abdul K. , Pratheeshkumar Poyil , Divya Sasidharan Padmaja , Parvathareddy Sandeep Kumar , Bu Rong , Masoodi Tariq , Kong Yan , Thangavel Saravanan , Al-Sanea Nasser , Ashari Luai H. , Abduljabbar Alaa , Al-Homoud Samar , Al-Dayel Fouad , Al-Kuraya Khawla S.
Published: April 2023

Effect of Smad4 manipulation on TGFβ induced CRC cell growth
Supplemental Figure 6 from Identification of Novel Ezrin Inhibitors Targeting Metastatic Osteosarcoma by Screening Open Access Malaria Box
Authors: Çelik Haydar , Hong Sung-Hyeok , Colón-López Daisy D. , Han Jenny , Kont Yasemin Saygideger , Minas Tsion Z. , Swift Matthew , Paige Mikell , Glasgow Eric , Toretsky Jeffrey A. , Bosch Jürgen , Üren Aykut
Published: April 2023

Effect of NSC305787 and the hits from MMV400 library on ezrin T567 phoshorylation
Supplementary Figures 1-7 from Loss of Notch1 Activity Inhibits Prostate Cancer Growth and Metastasis and Sensitizes Prostate Cancer Cells to Antiandrogen Therapies
Authors: Rice Meghan A. , Hsu En-Chi , Aslan Merve , Ghoochani Ali , Su Austin , Stoyanova Tanya
Published: April 2023

Supplementary Figure 1. Quantification of immunoblotting in Figure 1. Supplementary Figure 2. Animal weights from Figure 3 xenografts. Supplementary Figure 3. Quantification of immunoblotting from xenograft tissues in Figure 3. Supplementary Figure 4. Viability of GSI combination therapy with anti-androgens Enzalutamide or Abiraterone. Supplementary Figure 5. GSI and anti-Androgen therapies synergize to decrease colony formation of CRPC cells. Supplementary Figure 6. GSIs synergize with anti-androgens Enzalutamide and Abiraterone to inhibit prostate cancer cell migration in vitro. Supplementary Figure 7. Matrigel Dot assay performed on 22RV1 cells was not able to assay migration.
Supplemental Figure 4 from Identification of Novel Ezrin Inhibitors Targeting Metastatic Osteosarcoma by Screening Open Access Malaria Box
Authors: Çelik Haydar , Hong Sung-Hyeok , Colón-López Daisy D. , Han Jenny , Kont Yasemin Saygideger , Minas Tsion Z. , Swift Matthew , Paige Mikell , Glasgow Eric , Toretsky Jeffrey A. , Bosch Jürgen , Üren Aykut
Published: April 2023

Representative real time migration curves for K12 and K7M2 cells in response to vehicle (DMSO) or compound treatment as determined by electrical impedance expressed as cell index during 21 hr incubation
Supplementary Figure S1 from Mechanisms of Resistance to EGFR Inhibition Reveal Metabolic Vulnerabilities in Human GBM
Authors: McKinney Andrew , Lindberg Olle R. , Engler Jane R. , Chen Katharine Y. , Kumar Anupam , Gong Henry , Lu Kan V. , Simonds Erin F. , Cloughesy Timothy F. , Liau Linda M. , Prados Michael , Bollen Andrew W. , Berger Mitchel S. , Shieh Joseph T.C. , James C. David , Nicolaides Theodore P. , Yong William H. , Lai Albert , Hegi Monika E. , Weiss William A. , Phillips Joanna J.
Published: April 2023

Supplementary Figure S1 shows increased invasion is specific to EGFR inhibition, increased ALDH1A1 expression is not specific to erlotinib but also occurs with AG1478 and lapatinib, and EGFR inhibition increases expression of several genes implicated in cell adhesion and motility.
Supplemental Figure 2 from Identification of Novel Ezrin Inhibitors Targeting Metastatic Osteosarcoma by Screening Open Access Malaria Box
Authors: Çelik Haydar , Hong Sung-Hyeok , Colón-López Daisy D. , Han Jenny , Kont Yasemin Saygideger , Minas Tsion Z. , Swift Matthew , Paige Mikell , Glasgow Eric , Toretsky Jeffrey A. , Bosch Jürgen , Üren Aykut
Published: April 2023

Representative steady-state affinity curve of primary hits from MMV400 library for binding to ezrin as measured by SPR
Table S1-5 from Target Deconvolution of a Multikinase Inhibitor with Antimetastatic Properties Identifies TAOK3 as a Key Contributor to a Cancer Stem Cell–Like Phenotype
Authors: Bian Yansong , Teper Yaroslav , Mathews Griner Lesley A. , Aiken Taylor J. , Shukla Vivek , Guha Rajarshi , Shinn Paul , Xin Hong-Wu , Pflicke Holger , Powers Astin S. , Li Dandan , Jiang Jian-kang , Patel Paresma , Rogers Steven A. , Aubé Jeffrey , Ferrer Marc , Thomas Craig J. , Rudloff Udo
Published: April 2023

Suppl. Table 1. Origin of cancer cell lines used in this study. Suppl. Table 2. Quantitative HTS screen in PANC1 cells grown as spheroids. Results of full ten concentration drug-response curves of 1,912 individual agents and compounds in PANC1 spheroids. SID, Sample ID; CCLASS, Curve class; CCLASS2, Curve class (latest version); LAC50, log AC50 (M); HILL, Hill coefficient; ZERO, fitted response at minimum concentration; INF, Fitted response at maximum concentration; MAXR, Observed response at maximum concentration; DATA0 - DATA10, Responses; C0 - C10, Doses (in ÂµM); auc, Area Under the Curve (via integration of the fit). This data is available via the PubChem database (AID 1259363). Suppl. Table 3 Top twenty hits of KiNativ profiling of PANC1 cells with at least {greater than or equal to}50 percent inhibition of ADP binding following treatment with 500 nM of inhibitor #1. Suppl. Table 4. In vitro activity of inhibitor #1 against a panel of over 400 kinases (DiscoveRx's KinomeScan) and in situ activity of inhibitor #1 in PANC1 spheroid cells (KiNative). Suppl. Table 5. Outcomes of both 6Ã-6 and 10Ã-10 combination drug screening of inhibitor #1 versus a collection of approved and investigational drugs.
Supplementary Data from Rational Combination Therapy for Melanoma with Dinaciclib by Targeting BAK-Dependent Cell Death
Authors: Xu Xiaoou , Eshima Shizuka , Kato Shinichiro , Fisher David E. , Sakurai Hiroaki , Hayakawa Yoshihiro , Yokoyama Satoru
Published: April 2023

Supplementary Figure 1 shows that CDK2 and CDK9 are involved in BAK-dependent melanoma apoptosis induced by dinaciclib.Supplementary Figure 2 shows that BRAF inhibition suppresses melanoma through BAX. Supplementary Figure 3 shows combinational effects of dinaciclib with BAX-activating drugs.
Supplementary Figures S1-S4 from Efficacy and Tolerability of a GD2-Directed Trifunctional Bispecific Antibody in a Preclinical Model: Subcutaneous Administration Is Superior to Intravenous Delivery
Authors: Deppisch Nina , Ruf Peter , Eissler Nina , Neff Frauke , Buhmann Raymund , Lindhofer Horst , Mocikat Ralph
Published: April 2023

Supplementary Figures S1-S4. Supplementary Figure S1. Development of anti-antibodies following Surek treatment; Supplementary Figure S2. Activation and proliferation of T cells after treatment with trAb Surek alone; Supplementary Figure S3. Weight loss of mice after unspecific immune activation induced by CD3 binding of Surek; Supplementary Figure S4. Cytokine milieu induced by Surek s.c.
Supplementary Figure S5 from Inhibition of Ubiquitin-Specific Protease 14 Suppresses Cell Proliferation and Synergizes with Chemotherapeutic Agents in Neuroblastoma
Authors: Yu Yang , Zhao Yanling , Fan Yihui , Chen Zhenghu , Li Hui , Lu Jiaxiong , Guo Kevin , Woodfield Sarah E. , Vasudevan Sanjeev A. , Yang Jianhua , Nuchtern Jed G.
Published: April 2023

Correlation between USP14 and NB patients' outcomes.
Supplementary Tables 1 through 5, Supplementary Materials and Methods, and Supplementary Figure Legends from A Novel Inhibitor of AKT1–PDPK1 Interaction Efficiently Suppresses the Activity of AKT Pathway and Restricts Tumor Growth In Vivo
Authors: Mäemets-Allas Kristina , Viil Janeli , Jaks Viljar
Published: April 2023

Table S1. Antibodies used for Western Blotting. Table S2. Primers used for RT-QPCR. Table S3. Antibodies used for immunofluorescence analysis. Table S4. Vectors used for screening experiments. Table S5. 36 chemicals from 2000 selected for further investigation. Supplementary Methods. Supplementary figure legends.
Supplementary Figure S6 from A Novel Inhibitor of AKT1–PDPK1 Interaction Efficiently Suppresses the Activity of AKT Pathway and Restricts Tumor Growth In Vivo
Authors: Mäemets-Allas Kristina , Viil Janeli , Jaks Viljar
Published: April 2023

NSC156529 had no significant impact on cancer cell apoptosis
Supplementary Figure S1 from A Novel Inhibitor of AKT1–PDPK1 Interaction Efficiently Suppresses the Activity of AKT Pathway and Restricts Tumor Growth In Vivo
Authors: Mäemets-Allas Kristina , Viil Janeli , Jaks Viljar
Published: April 2023

Four selected chemicals did not alter the morphology of H1299 cell culture
Supplementary Table 1 from A High-Content Screening of Anticancer Compounds Suggests the Multiple Tyrosine Kinase Inhibitor Ponatinib for Repurposing in Neuroblastoma Therapy
Authors: Sidarovich Viktoryia , De Mariano Marilena , Aveic Sanja , Pancher Michael , Adami Valentina , Gatto Pamela , Pizzini Silvia , Pasini Luigi , Croce Michela , Parodi Federica , Cimmino Flora , Avitabile Marianna , Emionite Laura , Cilli Michele , Ferrini Silvano , Pagano Aldo , Capasso Mario , Quattrone Alessandro , Tonini Gian Paolo , Longo Luca
Published: April 2023

List of primary hits
Supplementary Figure S4 from A High-Content Screening of Anticancer Compounds Suggests the Multiple Tyrosine Kinase Inhibitor Ponatinib for Repurposing in Neuroblastoma Therapy
Authors: Sidarovich Viktoryia , De Mariano Marilena , Aveic Sanja , Pancher Michael , Adami Valentina , Gatto Pamela , Pizzini Silvia , Pasini Luigi , Croce Michela , Parodi Federica , Cimmino Flora , Avitabile Marianna , Emionite Laura , Cilli Michele , Ferrini Silvano , Pagano Aldo , Capasso Mario , Quattrone Alessandro , Tonini Gian Paolo , Longo Luca
Published: April 2023

In vivo imaging of IMR-32 tumor growth in NB orthotopic mice.
Supplementary Figure S3 from A High-Content Screening of Anticancer Compounds Suggests the Multiple Tyrosine Kinase Inhibitor Ponatinib for Repurposing in Neuroblastoma Therapy
Authors: Sidarovich Viktoryia , De Mariano Marilena , Aveic Sanja , Pancher Michael , Adami Valentina , Gatto Pamela , Pizzini Silvia , Pasini Luigi , Croce Michela , Parodi Federica , Cimmino Flora , Avitabile Marianna , Emionite Laura , Cilli Michele , Ferrini Silvano , Pagano Aldo , Capasso Mario , Quattrone Alessandro , Tonini Gian Paolo , Longo Luca
Published: April 2023

In vivo imaging of SK-N-BE(2) tumor growth in NB orthotopic mice.
Supplementary Figure S2 from A High-Content Screening of Anticancer Compounds Suggests the Multiple Tyrosine Kinase Inhibitor Ponatinib for Repurposing in Neuroblastoma Therapy
Authors: Sidarovich Viktoryia , De Mariano Marilena , Aveic Sanja , Pancher Michael , Adami Valentina , Gatto Pamela , Pizzini Silvia , Pasini Luigi , Croce Michela , Parodi Federica , Cimmino Flora , Avitabile Marianna , Emionite Laura , Cilli Michele , Ferrini Silvano , Pagano Aldo , Capasso Mario , Quattrone Alessandro , Tonini Gian Paolo , Longo Luca
Published: April 2023

Cell cycle and clonogenic profiles after treatments with ponatinib and axitinib.
Supplementary Figure S5 from Quantitative High-Throughput Screening Using an Organotypic Model Identifies Compounds that Inhibit Ovarian Cancer Metastasis
Authors: Kenny Hilary A. , Lal-Nag Madhu , Shen Min , Kara Betul , Nahotko Dominik A. , Wroblewski Kristen , Fazal Sarah , Chen Siquan , Chiang Chun-Yi , Chen Yen-Ju , Brimacombe Kyle R. , Marugan Juan , Ferrer Marc , Lengyel Ernst
Published: April 2023

Supplementary Figure S5 shows the activity of inert compounds and mTOR inhibitors in secondary biological in vivo adhesion/invasion assay.
Supplementary Figure S3 from Quantitative High-Throughput Screening Using an Organotypic Model Identifies Compounds that Inhibit Ovarian Cancer Metastasis
Authors: Kenny Hilary A. , Lal-Nag Madhu , Shen Min , Kara Betul , Nahotko Dominik A. , Wroblewski Kristen , Fazal Sarah , Chen Siquan , Chiang Chun-Yi , Chen Yen-Ju , Brimacombe Kyle R. , Marugan Juan , Ferrer Marc , Lengyel Ernst
Published: April 2023

Supplementary Figure S3 shows the activity of non-lead compounds in secondary confirmatory assays.
Supplemental Figure S1 from Quantitative High-Throughput Screening Using an Organotypic Model Identifies Compounds that Inhibit Ovarian Cancer Metastasis
Authors: Kenny Hilary A. , Lal-Nag Madhu , Shen Min , Kara Betul , Nahotko Dominik A. , Wroblewski Kristen , Fazal Sarah , Chen Siquan , Chiang Chun-Yi , Chen Yen-Ju , Brimacombe Kyle R. , Marugan Juan , Ferrer Marc , Lengyel Ernst
Published: April 2023

Supplementary Figure S1 shows the primary screen, protocol, layout and performance.
Supplementary Text from A Synergistic Anticancer FAK and HDAC Inhibitor Combination Discovered by a Novel Chemical–Genetic High-Content Phenotypic Screen
Authors: Dawson John C. , Serrels Bryan , Byron Adam , Muir Morwenna T. , Makda Ashraff , García-Muñoz Amaya , von Kriegsheim Alex , Lietha Daniel , Carragher Neil O. , Frame Margaret C.
Published: April 2023

Supplementary Materials and Methods.
Supplementary Table S2 from A Synergistic Anticancer FAK and HDAC Inhibitor Combination Discovered by a Novel Chemical–Genetic High-Content Phenotypic Screen
Authors: Dawson John C. , Serrels Bryan , Byron Adam , Muir Morwenna T. , Makda Ashraff , García-Muñoz Amaya , von Kriegsheim Alex , Lietha Daniel , Carragher Neil O. , Frame Margaret C.
Published: April 2023

FAK combination phenotypic screen data.
Supplementary Table S1 from A Synergistic Anticancer FAK and HDAC Inhibitor Combination Discovered by a Novel Chemical–Genetic High-Content Phenotypic Screen
Authors: Dawson John C. , Serrels Bryan , Byron Adam , Muir Morwenna T. , Makda Ashraff , García-Muñoz Amaya , von Kriegsheim Alex , Lietha Daniel , Carragher Neil O. , Frame Margaret C.
Published: April 2023

FAK kinase-dependent dysregulation of specific FAK-binding proteins.
Supplementary figure 1,2,3,4 and supplementary table 1 from Antibody Format and Drug Release Rate Determine the Therapeutic Activity of Noninternalizing Antibody–Drug Conjugates
Authors: Gébleux Rémy , Wulhfard Sarah , Casi Giulio , Neri Dario
Published: April 2023

Supplementary Fig S1 : Amino acid sequences of the constructs used. Supplementary Fig S2 : ESI-MS spectra depicting the SIP(F8)-SS-DM1 and the internal standard used. Supplementary Fig S3 : ESI-MS spectra of conjugated and unconjugated IgG(F8)-SS-DM1 Supplementary Fig S4 : Proposed mechanism of disulfides bridges formation in the SIP. Supplementary Table S1 : Detailed values of the Biodistribution data
Supplementary Fig. S4 from A Synergistic Anticancer FAK and HDAC Inhibitor Combination Discovered by a Novel Chemical–Genetic High-Content Phenotypic Screen
Authors: Dawson John C. , Serrels Bryan , Byron Adam , Muir Morwenna T. , Makda Ashraff , García-Muñoz Amaya , von Kriegsheim Alex , Lietha Daniel , Carragher Neil O. , Frame Margaret C.
Published: April 2023

Analysis of HDAC and FAK inhibition in A549 and Flo1 cell lines.
Supplementary Table 2 from AZD5153: A Novel Bivalent BET Bromodomain Inhibitor Highly Active against Hematologic Malignancies
Authors: Rhyasen Garrett W. , Hattersley Maureen M. , Yao Yi , Dulak Austin , Wang Wenxian , Petteruti Philip , Dale Ian L. , Boiko Scott , Cheung Tony , Zhang Jingwen , Wen Shenghua , Castriotta Lillian , Lawson Deborah , Collins Michael , Bao Larry , Ahdesmaki Miika J. , Walker Graeme , O'Connor Greg , Yeh Tammie C. , Rabow Alfred A. , Dry Jonathan R. , Reimer Corinne , Lyne Paul , Mills Gordon B. , Fawell Stephen E. , Waring Michael J. , Zinda Michael , Clark Edwin , Chen Huawei
Published: April 2023

Differentially expressed genes with AZD5153 treatment
Supplementary Table 1 from AZD5153: A Novel Bivalent BET Bromodomain Inhibitor Highly Active against Hematologic Malignancies
Authors: Rhyasen Garrett W. , Hattersley Maureen M. , Yao Yi , Dulak Austin , Wang Wenxian , Petteruti Philip , Dale Ian L. , Boiko Scott , Cheung Tony , Zhang Jingwen , Wen Shenghua , Castriotta Lillian , Lawson Deborah , Collins Michael , Bao Larry , Ahdesmaki Miika J. , Walker Graeme , O'Connor Greg , Yeh Tammie C. , Rabow Alfred A. , Dry Jonathan R. , Reimer Corinne , Lyne Paul , Mills Gordon B. , Fawell Stephen E. , Waring Michael J. , Zinda Michael , Clark Edwin , Chen Huawei
Published: April 2023

Cell line authentication information
Supplementary Figures 1-5 from AZD5153: A Novel Bivalent BET Bromodomain Inhibitor Highly Active against Hematologic Malignancies
Authors: Rhyasen Garrett W. , Hattersley Maureen M. , Yao Yi , Dulak Austin , Wang Wenxian , Petteruti Philip , Dale Ian L. , Boiko Scott , Cheung Tony , Zhang Jingwen , Wen Shenghua , Castriotta Lillian , Lawson Deborah , Collins Michael , Bao Larry , Ahdesmaki Miika J. , Walker Graeme , O'Connor Greg , Yeh Tammie C. , Rabow Alfred A. , Dry Jonathan R. , Reimer Corinne , Lyne Paul , Mills Gordon B. , Fawell Stephen E. , Waring Michael J. , Zinda Michael , Clark Edwin , Chen Huawei
Published: April 2023

Supplementary Figure 1. AZD5153 shows reduced BRD4 binding activity when BD2 function is abolished; Supplementary Figure 2. AZD5153 modulates MYC protein levels across hematologic cancer cell lines; Supplementary Figure 3. Gene Ontology (GO) analysis of the down-regulated transcripts by AZD5153 across all cell line types; Supplementary Figure 4. IC50 and percent maximal cell kill by AZD5153 and I-BET762 in five hematologic cell lines; Supplementary Figure 5. Tumor growth inhibition across six hematological xenograft Models
Supplementary Data from Verticillin A Causes Apoptosis and Reduces Tumor Burden in High-Grade Serous Ovarian Cancer by Inducing DNA Damage
Authors: Salvi Amrita , Amrine Chiraz Soumia M. , Austin Julia R. , Kilpatrick KiAundra , Russo Angela , Lantvit Daniel , Calderon-Gierszal Esther , Mattes Zachary , Pearce Cedric J. , Grinstaff Mark W. , Colby Aaron H. , Oberlies Nicholas H. , Burdette Joanna E.
Published: April 2023

Supplementary Figure S1 shows histone post-translational modifications (B) and qRT-PCR validation (C) of RNA-seq data for vehicle (DMSO) and verticillin A treated OVCAR8 cells. Supplementary Figure S2 shows Verticillin A-eNP synthesis procedure (A), scanning electron micrograph of verticillin A expansile nanoparticles (B) and calibration curve for verticillin A (C). Supplementary Figure S3 shows structure of verticillin A (A), 1H-NMR (B) and UPLC (C) data for estimating purity of verticillin A, Supplementary Figure S4 shows mitochondrial toxicity assay for verticillin A
Supplemetal Figures 1 and 2 from RN927C, a Site-Specific Trop-2 Antibody–Drug Conjugate (ADC) with Enhanced Stability, Is Highly Efficacious in Preclinical Solid Tumor Models
Authors: Strop Pavel , Tran Thomas-Toan , Dorywalska Magdalena , Delaria Kathy , Dushin Russell , Wong Oi Kwan , Ho Wei-Hsien , Zhou Dahui , Wu Aidong , Kraynov Eugenia , Aschenbrenner Laura , Han Bora , O'Donnell Christopher J. , Pons Jaume , Rajpal Arvind , Shelton Dave L. , Liu Shu-Hui
Published: April 2023

Supplementary Figure S1.RN927C induced mitotic arrest of pancreatic PDX tumors in vivo; Supplementary Figure S2. Unconjugated anti-Trop-2 antibody reduced RN927C in vivo efficacy
Supplemental Figure Legend from Anti-Endosialin Antibody–Drug Conjugate: Potential in Sarcoma and Other Malignancies
Authors: Rouleau Cecile , Gianolio Diego A. , Smale Robert , Roth Stephanie D. , Krumbholz Roy , Harper Jay , Munroe Kenneth J. , Green Tessa L. , Horten Bruce C. , Schmid Steven M. , Teicher Beverly A.
Published: April 2023

Supplemental Figure Legend from Anti-Endosialin Antibody–Drug Conjugate: Potential in Sarcoma and Other Malignancies
Supplemental Figure 1 from Anti-Endosialin Antibody–Drug Conjugate: Potential in Sarcoma and Other Malignancies
Authors: Rouleau Cecile , Gianolio Diego A. , Smale Robert , Roth Stephanie D. , Krumbholz Roy , Harper Jay , Munroe Kenneth J. , Green Tessa L. , Horten Bruce C. , Schmid Steven M. , Teicher Beverly A.
Published: April 2023

Chart showing body weight change after administration of the ADC.
Video-Supplementary Fig. 2b from Dinaciclib Induces Anaphase Catastrophe in Lung Cancer Cells via Inhibition of Cyclin-Dependent Kinases 1 and 2
Authors: Danilov Alexey V. , Hu Shanhu , Orr Bernardo , Godek Kristina , Mustachio Lisa Maria , Sekula David , Liu Xi , Kawakami Masanori , Johnson Faye M. , Compton Duane A. , Freemantle Sarah J. , Dmitrovsky Ethan
Published: April 2023

Movie video files of HOP62 cells as described in the Methods.
Video-Supplementary Fig. 2a from Dinaciclib Induces Anaphase Catastrophe in Lung Cancer Cells via Inhibition of Cyclin-Dependent Kinases 1 and 2
Authors: Danilov Alexey V. , Hu Shanhu , Orr Bernardo , Godek Kristina , Mustachio Lisa Maria , Sekula David , Liu Xi , Kawakami Masanori , Johnson Faye M. , Compton Duane A. , Freemantle Sarah J. , Dmitrovsky Ethan
Published: April 2023

Movie video files of a) H1299 as described in the Methods.
Table S4 from eIF4A Inhibitors Suppress Cell-Cycle Feedback Response and Acquired Resistance to CDK4/6 Inhibition in Cancer
Authors: Kong Tim , Xue Yibo , Cencic Regina , Zhu Xianbing , Monast Anie , Fu Zheng , Pilon Virginie , Sangwan Veena , Guiot Marie-Christine , Foulkes William D. , Porco John A. , Park Morag , Pelletier Jerry , Huang Sidong
Published: April 2023

Supplemental Table 4.Quantification of cell viability after drug combination treatment
Table S2 from eIF4A Inhibitors Suppress Cell-Cycle Feedback Response and Acquired Resistance to CDK4/6 Inhibition in Cancer
Authors: Kong Tim , Xue Yibo , Cencic Regina , Zhu Xianbing , Monast Anie , Fu Zheng , Pilon Virginie , Sangwan Veena , Guiot Marie-Christine , Foulkes William D. , Porco John A. , Park Morag , Pelletier Jerry , Huang Sidong
Published: April 2023

Supplemental Table 2.Quantification of cell proliferative colony formation assays
Table S1 from eIF4A Inhibitors Suppress Cell-Cycle Feedback Response and Acquired Resistance to CDK4/6 Inhibition in Cancer
Authors: Kong Tim , Xue Yibo , Cencic Regina , Zhu Xianbing , Monast Anie , Fu Zheng , Pilon Virginie , Sangwan Veena , Guiot Marie-Christine , Foulkes William D. , Porco John A. , Park Morag , Pelletier Jerry , Huang Sidong
Published: April 2023

Supplemental Table 1.Quantification of immunoblots.
Supplemental Figure Legend from ADA-07 Suppresses Solar Ultraviolet–Induced Skin Carcinogenesis by Directly Inhibiting TOPK
Authors: Gao Ge , Zhang Tianshun , Wang Qiushi , Reddy Kanamata , Chen Hanyong , Yao Ke , Wang Keke , Roh Eunmiri , Zykova Tatyana , Ma Weiya , Ryu Joohyun , Curiel-Lewandrowski Clara , Alberts David , Dickinson Sally E. , Bode Ann M. , Xing Ying , Dong Zigang
Published: April 2023

Supplemental Figure Legend
Supplementary Table S1 from Intermittent High-Dose Scheduling of AZD8835, a Novel Selective Inhibitor of PI3Kα and PI3Kδ, Demonstrates Treatment Strategies for PIK3CA-Dependent Breast Cancers
Authors: Hudson Kevin , Hancox Urs J. , Trigwell Cath , McEwen Robert , Polanska Urszula M. , Nikolaou Myria , Morentin Gutierrez Pablo , Avivar-Valderas Alvaro , Delpuech Oona , Dudley Phillippa , Hanson Lyndsey , Ellston Rebecca , Jones Alys , Cumberbatch Marie , Cosulich Sabina C. , Ward Lara , Cruzalegui Francisco , Green Stephen
Published: April 2023

Details on cell lines used in AZD8835 selectivity profiling and efficacy studies.
Supplementary File S2 from Intermittent High-Dose Scheduling of AZD8835, a Novel Selective Inhibitor of PI3Kα and PI3Kδ, Demonstrates Treatment Strategies for PIK3CA-Dependent Breast Cancers
Authors: Hudson Kevin , Hancox Urs J. , Trigwell Cath , McEwen Robert , Polanska Urszula M. , Nikolaou Myria , Morentin Gutierrez Pablo , Avivar-Valderas Alvaro , Delpuech Oona , Dudley Phillippa , Hanson Lyndsey , Ellston Rebecca , Jones Alys , Cumberbatch Marie , Cosulich Sabina C. , Ward Lara , Cruzalegui Francisco , Green Stephen
Published: April 2023

Details on PK / PD / efficacy modeling in BT474 xenograft model
Supplemental Figure 2 from ADA-07 Suppresses Solar Ultraviolet–Induced Skin Carcinogenesis by Directly Inhibiting TOPK
Authors: Gao Ge , Zhang Tianshun , Wang Qiushi , Reddy Kanamata , Chen Hanyong , Yao Ke , Wang Keke , Roh Eunmiri , Zykova Tatyana , Ma Weiya , Ryu Joohyun , Curiel-Lewandrowski Clara , Alberts David , Dickinson Sally E. , Bode Ann M. , Xing Ying , Dong Zigang
Published: April 2023

The expression level of TOPK in normal skin cells (JB6 P+, NHDF) and skin cancer cells (A431 and SCC12). TOPK expression was assessed by Western blot using a specific antibody and β-actin was used as a loading control.
Supplemental Figure 1 from ADA-07 Suppresses Solar Ultraviolet–Induced Skin Carcinogenesis by Directly Inhibiting TOPK
Authors: Gao Ge , Zhang Tianshun , Wang Qiushi , Reddy Kanamata , Chen Hanyong , Yao Ke , Wang Keke , Roh Eunmiri , Zykova Tatyana , Ma Weiya , Ryu Joohyun , Curiel-Lewandrowski Clara , Alberts David , Dickinson Sally E. , Bode Ann M. , Xing Ying , Dong Zigang
Published: April 2023

ADA-07 synthesis, MS analysis and cytotoxicity assays.
Supplementary Table S2 from In Vitro and In Vivo Activity of AMG 337, a Potent and Selective MET Kinase Inhibitor, in MET-Dependent Cancer Models
Authors: Hughes Paul E. , Rex Karen , Caenepeel Sean , Yang Yajing , Zhang Yihong , Broome Martin A. , Kha Hue T. , Burgess Teresa L. , Amore Benny , Kaplan-Lefko Paula J. , Moriguchi Jodi , Werner Jonathan , Damore Michael A. , Baker Daniel , Choquette Deborah M. , Harmange Jean-Christophe , Radinsky Robert , Kendall Richard , Dussault Isabelle , Coxon Angela
Published: April 2023

High-level focal amplification of MET is associated with sensitivity to AMG 337
Supplementary Figure S2 from Intermittent High-Dose Scheduling of AZD8835, a Novel Selective Inhibitor of PI3Kα and PI3Kδ, Demonstrates Treatment Strategies for PIK3CA-Dependent Breast Cancers
Authors: Hudson Kevin , Hancox Urs J. , Trigwell Cath , McEwen Robert , Polanska Urszula M. , Nikolaou Myria , Morentin Gutierrez Pablo , Avivar-Valderas Alvaro , Delpuech Oona , Dudley Phillippa , Hanson Lyndsey , Ellston Rebecca , Jones Alys , Cumberbatch Marie , Cosulich Sabina C. , Ward Lara , Cruzalegui Francisco , Green Stephen
Published: April 2023

Timecourses showing transient glucose / insulin elevations in mice following AZD8835 dosing.
Supplementary Table S1 from In Vitro and In Vivo Activity of AMG 337, a Potent and Selective MET Kinase Inhibitor, in MET-Dependent Cancer Models
Authors: Hughes Paul E. , Rex Karen , Caenepeel Sean , Yang Yajing , Zhang Yihong , Broome Martin A. , Kha Hue T. , Burgess Teresa L. , Amore Benny , Kaplan-Lefko Paula J. , Moriguchi Jodi , Werner Jonathan , Damore Michael A. , Baker Daniel , Choquette Deborah M. , Harmange Jean-Christophe , Radinsky Robert , Kendall Richard , Dussault Isabelle , Coxon Angela
Published: April 2023

Enzymatic and cellular potency of Amgen Compound 5
Supplementary Figure S1 from Intermittent High-Dose Scheduling of AZD8835, a Novel Selective Inhibitor of PI3Kα and PI3Kδ, Demonstrates Treatment Strategies for PIK3CA-Dependent Breast Cancers
Authors: Hudson Kevin , Hancox Urs J. , Trigwell Cath , McEwen Robert , Polanska Urszula M. , Nikolaou Myria , Morentin Gutierrez Pablo , Avivar-Valderas Alvaro , Delpuech Oona , Dudley Phillippa , Hanson Lyndsey , Ellston Rebecca , Jones Alys , Cumberbatch Marie , Cosulich Sabina C. , Ward Lara , Cruzalegui Francisco , Green Stephen
Published: April 2023

Timecourse of PI3K pathway inhibition in MCF7 cells illustrating pathway reactivation over time.
Supplementary Figure S1 from MTORC1/2 Inhibition as a Therapeutic Strategy for PIK3CA Mutant Cancers
Authors: Fricke Stephanie L. , Payne Susan N. , Favreau Peter F. , Kratz Jeremy D. , Pasch Cheri A. , Foley Tyler M. , Yueh Alexander E. , Van De Hey Dana R. , Depke Mitchell G. , Korkos Demetra P. , Sha Gioia Chengcheng , DeStefanis Rebecca A. , Clipson Linda , Burkard Mark E. , Lemmon Kayla K. , Parsons Benjamin M. , Kenny Paraic A. , Matkowskyj Kristina A. , Newton Michael A. , Skala Melissa C. , Deming Dustin A.
Published: April 2023

Supplementary Figure S1 presents the viability of SW48 and SW48PK cells after treatment with BEZ235 and TAK-228 at the 100-400nM concentrations.
Table S1 from In Vivo Antitumoral Efficacy of PhAc-ALGP-Doxorubicin, an Enzyme-Activated Doxorubicin Prodrug, in Patient-Derived Soft Tissue Sarcoma Xenograft Models
Authors: Cornillie Jasmien , Wozniak Agnieszka , Pokreisz Peter , Casazza Andrea , Vreys Lise , Wellens Jasmien , Vanleeuw Ulla , Gebreyohannes Yemarshet K. , Debiec-Rychter Maria , Sciot Raf , Hompes Daphne , Schöffski Patrick
Published: April 2023

Detailed description of the number of mice/tumors and the doses of drugs in all in vivo experiments.